EpicQuest Gains on Deal with Jishi
EpicQuest Education Group International Limited (NASDAQ: EEIQ), a provider of higher education for domestic and international students in the U.S., Canada and the U.K., today announced that its owned and operated Davis University entered into an agreement with Jishi Holdings (Guangdong) Co. Ltd., established by the School of Artificial Intelligence, the Chinese University of Hong Kong, Shenzhen, for the Company to establish a foundational program on the Shenzhen campus of the Chinese University of Hong Kong. The Agreement is effective until August 31, 2027.EpicQuest CEO Jianbo Zhang commented, "Although the program commenced just this month, we have already admitted 20 students with plans to enroll up to 60 students in this new program. “Our foundational programs represent a distinct revenue stream for the Company, and they enable students to study in their home countries to gain the skills needed for study abroad. The agreement represents our fourth foundational program, and all of our programs are with first-class and internationally renowned universities."EEIQ's Davis University foundational programs constitute a course of study for students to acquire the skills needed for Davis University's bachelor's degree programs as well as pathways for admission to other U.S. universities. The Company also has foundational programs at other elite universities in China.EEIQ stock acquired six cents, or 11%, to 58 cents.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


